<DOC>
	<DOC>NCT03081936</DOC>
	<brief_summary>This pilot study primarily aimed to compare effects of breast feeding, A1 versus A2Â®cow milk based formula on alimentation and gastrointestinal digestion. The impact of the study products on fecal myeloperoxidase (MPO), short-chain fatty acid (SCFA), secretory immunoglobulin A (sIgA) concentration, gastrointestinal tolerance, defecating habit and infant growth were also evaluated.</brief_summary>
	<brief_title>Comparative A1 vs A2 Formula and Breast Feeding on Alimentation and Gastrointestinal Digestion for the Infant</brief_title>
	<detailed_description />
	<criteria>Willing to formula feeding and consume 600ml or more of IF each day; Have normal electrocardiograms (ECG) and blood pressure during quiet respiration. Agree not to take any medication, supplements, nutrition or other dairy products including acidophilus milk; Parent(s) or legal guardian's consent to the study and willing to comply with study procedures; Parent(s) or guardian of infant agrees not to enroll infant another clinical study while participating in this study; Fully understand the nature, objective, benefit and the potential risks and side effects of the study. Twins, multiple birth, low birth weight children, over birth weight children or early birth children with gestational age less than 37 weeks; During pregnancy, the mothers had pregnancy complications or other disease that may affect the results; Having serious diseases that may affect study interventions, such as neonatal sepsis, pneumonia (associated with respiratory failure), heart failure and other disease; Having neonatal diarrhea or acute respiratory infections within 48hours before enrollment; Having potential metabolic diseases, chronic diseases, congenital malformations, central nervous system disorders, neuromuscular disorders or diseases affecting bone metabolism that may affect growth or the study results; Having taken any food containing prebiotics or probiotics tithing 15 days of enrollment; Body weighttoheight Zvalue &lt;3 according to the standard of the World Health Organization (WHO); Receiving hormone therapy and intravenous nutrition; Lactose intolerance or allergic to ingredients of study product; Have history of faecal impaction; Have participated in similar dairy or probioticscontaining product's clinical trials within 3 months before the screening; Currently taking medicines for cardiovascular or metabolic disease ; Currently suffering from any gastrointestinal disorders or gastrointestinal disease , including but not limited to: irritable bowel syndrome, colitis, ulcerative colitis, celiac disease, irritable bowel syndrome(IBS); Had hospitalizations within 3 months before screening; According to investigator's judgment, current frequent users of drugs which may affect the gastrointestinal function or immune system; Unable to comply the study schedule.</criteria>
	<gender>All</gender>
	<minimum_age>40 Days</minimum_age>
	<maximum_age>60 Days</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>